

Structural and functional brain abnormalities in mouse models of Lafora disease

Daniel F. Burgos^{1‡}, Lorena Cussó^{2,3,4,5‡}, Gentzane Sánchez-Elexpuru^{1,6‡}, Daniel Calle^{3,4}, Max Bautista Perpinya¹, Manuel Desco^{2,3,4,5}, José M. Serratosa¹, Marina P. Sánchez^{1*}

Supplementary Figures

Supplementary Figure S1: VBM analysis of MRI in hippocampus and cerebellum of Lafora disease mice.

Supplementary Figure S2: Brain metabolite alterations observed *ex-vivo* by ¹H-HRMAS analysis in young *Epm2a*^{-/-} and *Epm2b*^{-/-} mice.




Figure S2. Brain metabolite alterations observed *ex-vivo* by ^1H -HRMAS analysis in 6-month-old *Epm2a*^{-/-} and *Epm2b*^{-/-} mice. Graphic representation of data collected in Table 1. Metabolites assessed were acetate (Ace), alanine (Ala), aspartate (Asp), choline (Cho), creatine (Cr), gamma-aminobutyric acid (GABA), glucose (Glc), glutamine (Gln), glutamate (Glu), glycine (Gly), glutathione (GSH), glycerylphosphorylcholine (GPC), lactate (Lac), leucine (Leu), *myo*-Inositol (*mIns*), N-acetylaspartate (NAA), phosphatidylethanolamine (PE), phosphocholine (PCho), phosphocreatine (PCr), taurine (Tau), threonine (Thr), Cr from methylene protons (CrCH₂), Cho+GPC+PCho, Cr+PCr, Glu+Gln, Lip13a, MM09, MM20, MM12, MM14, Lip20, Lip13a+Lip13, MM14, Lip13, MM09+Lip09, MM20+Lip20. Of all of them, only Ace, Ala, Asp, Cr, GABA, GPC, Lac, *mIns*, NAA, PCho, PCr, Glu+Gln, *mIns*+Gly and Cho+GPC+PCho showed significant altered values. In *Epm2a*^{-/-} mice, Ace concentration normalized to tCr was statistically significant augmented in hippocampus, brainstem and cerebellum, while in *Epm2b*^{-/-} mice, an increase of this

metabolite was only observed in brainstem (Fig. S2A). In *Epm2a*^{-/-} mice, an increase of Ala/tCr ratio was observed in cortex and cerebellum (Fig. S2B), with an increase of Asp/tCr ratio in basal ganglia and a decrease in brainstem (Fig. S2C). In *Epm2b*^{-/-} mice, Asp/tCr increased in prefrontal cortex, while it decreased in brainstem (Table 1 and Supplementary Fig. S2C). GABA/tCr ratio augmented in cortex, hippocampus and hypothalamus of both models and also in thalamus and cerebellum of *Epm2a*^{-/-} mice (Table 1 and Supplementary Fig. S2E). GPC/tCr ratio increased in prefrontal cortex and decreased in brainstem of *Epm2b*^{-/-} mice, and it was not altered in *Epm2a*^{-/-} mice (Table 1 and Supplementary Fig. S2F). Lac normalized to tCr increased in cortex, prefrontal cortex and basal ganglia of both models, and also in hippocampus of *Epm2b*^{-/-} mice (Table 1 and Supplementary Fig. S2G). *mIns*/tCr and *mIns*+Gly/tCr ratios increased in cortex, prefrontal cortex and thalamus of *Epm2a*^{-/-} mice, whilst *mIns*/tCr also increased in brainstem of *Epm2a*^{-/-} mice and in prefrontal cortex of *Epm2b*^{-/-} mice. *mI*+Gly/tCr ratio increased in hippocampus of *Epm2a*^{-/-} mice and in cortex of *Epm2b*^{-/-} mice (Table 1 and Supplementary Fig. S2H and N). NAA/tCr decreased in all regions analyzed of *Epm2a*^{-/-} and *Epm2b*^{-/-} mice, with the exception of cortex and prefrontal cortex (Table 1 and Supplementary Fig. S2I). PCho/tCr decreased in thalamus of *Epm2a*^{-/-} mice (Table 1 and Supplementary Fig. S2J) and Cho+GPC+PCh/tCr decreased in basal ganglia of *Epm2b*^{-/-} mice (Table 1 and Supplementary Fig. S2L). Glu+Gln/tCr ratio decreased in hippocampus, brainstem and basal ganglia of both models and in cerebellum of *Epm2a*^{-/-} mice (Table 1 and Supplementary Fig. S2M). Cortex (Cx), prefrontal cortex (PFCx), hippocampus (Hippo), hypothalamus (Hyp), thalamus (Thal), brainstem (BS), basal ganglia (BG) and cerebellum (Cb). *p<0.05; **p<0.01; ***p<0.001.